Project Grant HT94252410337
Award Date
5/1/24
Completion Date
4/30/27
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68198, USA
Similar Awards
The Defense Health Agency awarded a $602,814 Project Grant to the University of Nebraska Medical Center (UNMC) under the Military Medical Research and Development program (CFDA 12.420). The grant, with a performance period from November 1, 2024 to October 31, 2027, supports research to investigate "Targeting Extracellular Nucleoside Metabolism as a Strategy to Potentiate the Effects of Immunotherapy in Pancreatic Ductal Adenocarcinoma." The project aims to explore innovative approaches...
The University of Nebraska Medical Center (UNMC) was awarded a $927,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "TARGETING FGFR4 SIGNALING TO OVERCOME CHEMORESISTANCE IN OVARIAN CANCER". The grant has an award date of July 1, 2024 and an ultimate completion date of June 30, 2028. UNMC, a leading institution in health sciences education, innovative research, and patient care, will...
This $602,550 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) supports adoptive cellular therapy research for pancreatic cancer. The awardee, the University of Nebraska Medical Center (UNMC), will conduct innovative biomedical research to develop novel therapeutic approaches, perform clinical trials, and provide technical expertise in this critical medical field. As a prominent academic research...
The Defense Health Agency awarded a $183,220 Project Grant to the University of Nebraska Medical Center (UNMC) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "Targeting the CCL17/CCR4 Axis to Eradicate Lung Cancer Brain Metastasis," supports research focused on developing innovative approaches to treat lung cancer brain metastasis. The research conducted under this grant will investigate the CCL17/CCR4 axis, a signaling...
The Defense Health Agency awarded a $579,375 Project Grant to the University of Nebraska Medical Center to support research targeting APE1 interaction with DNA G-quadruplex to prevent metastasis in triple-negative breast cancer. The grant is funded through the Military Medical Research and Development program (CFDA 12.420) and aims to transform health care for service members and the public through innovative biomedical research investigating medical solutions for the battlefield. The University...
This federal Project Grant award for $772,501.00, awarded on May 1, 2024 by the Defense Health Agency, supports the University of Nebraska Medical Center's research project titled "BUTYRYLCHOLINESTERASE: AN OUTSTANDING DIAGNOSTIC AND DRUGGABLE BIOMARKER IN UVEAL MELANOMA." The project, funded under the Military Medical Research and Development program (CFDA 12.420), aims to advance research into butyrylcholinesterase as a diagnostic and therapeutic target for uveal melanoma, a rare and...
The federal Project Grant award of $846,220 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to the Board of Regents of the University of Nebraska Medical Center (UNMC) on March 1, 2024. The award supports a 3-year research project titled "The Role of Astrocyte in Sleep Impairments in ASD" that aims to investigate the link between astrocyte function and sleep disturbances in individuals with autism spectrum...
The Board of Regents of the University of Nebraska received a $300,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant funds research on "SOMATIC MUTATIONS IN NON-IG LOCI IN AUTOREACTIVE B CELLS AS DRIVERS OF LUPUS PATHOGENESIS AND DISEASE HETEROGENEITY" being conducted at the University of Nebraska Medical Center in Omaha, Nebraska from July 1, 2023 through June 30, 2025. The Military...
The Defense Health Agency awarded a $579,375 Project Grant to the University of Nebraska Medical Center through the Military Medical Research and Development program (CFDA 12.420) to support research targeting APE1 interaction with DNA G-quadruplex to prevent metastasis in triple-negative breast cancer. The three-year award beginning December 30, 2022 will fund research by the University of Nebraska Medical Center to investigate medical solutions for metastatic breast cancer through innovative...
The Department of the Army Medical Command, through the Military Medical Research and Development federal grant program (CFDA 12.420), awarded a $556,200.00 project grant to the University of Nebraska Medical Center (UNMC) for "ADOPTIVE CELLULAR THERAPY FOR PANCREATIC CANCER". The award, with a period of performance from October 1, 2024 to September 30, 2027, will fund advanced biomedical research to develop innovative treatments for pancreatic cancer. UNMC, a prominent academic...